Navigation Links
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
Date:11/25/2008

SOUTH SAN FRANCISCO, Calif., Nov. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced that data from two ongoing Phase 2 clinical trials of carfilzomib in multiple myeloma will be presented at the upcoming 50th Annual Meeting of the American Society of Hematology (ASH). Carfilzomib is the first in a new class of specific proteasome inhibitors and is currently in multiple clinical trials for hematologic malignancies and solid tumors. This year's ASH conference will be held December 6-9, 2008 at the George Moscone Center in San Francisco, California.

Sundar Jagannath, M.D., Chief of the Multiple Myeloma Program, Bone Marrow and Blood Stem Cell Transplantation at St. Vincent's Comprehensive Cancer Center in New York will present initial results from Proteolix's Phase 2 study of carfilzomib for the treatment of patients with relapsed and refractory multiple myeloma during the Novel Therapies for Myeloma and Related Disorders session at 7:00 a.m. on Tuesday, December 9, 2008. This ongoing Phase 2 trial is an open-label multi-center study of single-agent carfilzomib in patients who have previously failed at least two prior treatments, containing bortezomib and either lenalidomide or thalidomide, and are refractory to their last treatment. Data from a second ongoing Phase 2 clinical trial of single-agent carfilzomib in relapsed multiple myeloma patients (stratified by prior therapy with bortezomib) will be presented immediately thereafter at 7:15 a.m. by Ravi Vij, M.D., Associate Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine.

In addition to the oral presentations, the company will have several poster presentations highlighting the results of preclinical studies that further characterize
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. today ... Inc. for the compounding, packaging and distributing of its naltrexone ... the United States . KRS ... compounding naltrexone tablets in various strengths for individual patients in ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... /PRNewswire-Asia-FirstCall/ --  3SBio Inc. (NASDAQ: SSRX ... on researching, developing, manufacturing and marketing biopharmaceutical products, ... fourth  quarter and full year  2011 results after ...  8, 2012 at 8:00pm (US Eastern). ...
... ,SARAH, - a French national collaborative randomized controlled ... sorafenib in advanced hepatocellular carcinoma is now open ... a new randomized controlled trial to directly compare ... (SIR-Spheres ® microspheres; Sirtex Medical Limited, Australia) ...
Cached Medicine Technology:3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2011 Results 2New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 2New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 3New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 4
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... comprising of 5461 girls between 11 to 15 yrs of ... more prone to stress fractures. ,The study shows that ... which often lasts for 16 or more hours per week. ... a stress fracture than the girls doing physical activity for ...
... that tumor necrosis factor (TNF)-á-blocking therapy used for ... ,The study done by the Dutch scientists ... Netherlands had taken into account the number and ... with the TNF-á-blocking therapy. 128 dermatological conditions in ...
... US have found out that body mass index are ... ,3216 people who had never been given any medication ... systolic and diastolic blood pressure. Body mass index could ... and diastolic blood pressure. The BMI could also be ...
... onions may be the key to avoid the risk of ... in onions, a peptide called GPCS that seems to prevent ... cells of newborn mice that were treated with parathyroid hormone ... exposed to the peptide GPCS. The treatment with the peptide ...
... National Cancer Institute Maryland USA had found out a gene ... Hutchinson-Gilford progeria syndrome. ,The disease is caused by ... is one of the major genes that lead to the ... from the individual with the disease have severe abnormalities in ...
... study is staking a claim that there may be evidence of ... of //diabetes. In the cases where there are evidence of insulin ... both are related to Alzheimer's disease. ,The findings, which ... Disease, say that insulin is not only produced in pancreas, but ...
Cached Medicine News:
Inquire...
Thermometer for Round Water Bath...
... The F340 is a basic laboratory ... compensated pH results can be obtained when ... a 3-in-1 electrode. • Fast and easy ... buffer recognition for five buffers (pH 1.68, ...
... laboratory system for pH and temperature measurements. ... when used with a temperature probe (ATC) ... easy one and two-point calibration with Auto-Find ... 1.68, 4.00, 7.00, 10.01 and 12.45) and ...
Medicine Products: